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Genetic polymorphismAbstract Background: Sirtuins (SIRT) have recently been identiﬁed as the pivotal regulators of
lifespan and health. SIRT1 has protective effects against cardiovascular disease (CVD) and through
its deacetylase activity it regulates numerous essential pathways including regulating blood pres-
sure, reducing atherosclerosis, heart protection against oxidative stress and inducing cardiac cell
survival and growth.
Aims: Therefore, this study was conducted to evaluate whether two genetic polymorphisms of
SIRT1 rs3758391 T/C and rs369274325 G/T are associated with the risk of CVD.
Material and methods: A total of 500 Iranian subjects including 250 CVD patients and 250
healthy individuals as the control group were recruited in this case–control study. Genotyping of
SIRT1 rs3758391 T/C and rs369274325 G/T polymorphisms were performed using PCR-RFLP
and Tetra-ARMS PCR methods, respectively.
Results: Our ﬁndings indicated a signiﬁcant difference between two groups regarding the SIRT1
rs3758391 CC genotype in both additive and recessive models. The rs3758391 CC genotype was
found to be more frequent in CVD patients than in the controls (19% vs. 6%), suggesting a statis-
tically signiﬁcant difference in either of additive (CC vs. TT; OR= 3.06, P= 0.001) as well as
recessive models (CC vs. TT + CT genotype; OR= 3.72, P= 0.001).
Conclusion: Our study for the ﬁrst time suggests that the SIRT1 rs3758391 T/C polymorphism
may confer an increased risk of CVD in both additive and recessive models, in this Iranian popu-
lation.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
In the last decades the worldwide population has demon-
strated a mounting life expectancy with a consequent rise in
the elderly population, resulting in enhanced health and social
costs. Cardiovascular diseases (CVD) rise with aging and are
118 N. Mohtavinejad et al.one of the foremost causes of fatality all over the world.
Numerous risk factors have been characterized for CVD, but
atherosclerosis, hypertension, insulin resistance and dyslipide-
mia are considered to be the most crucial factors associated
with higher incidence of CVD [1–3].
The sirtuins (Silent information regulator of transcription
or SIRT), a family of enzymes, have recently been identiﬁed
as the pivotal regulators of lifespan and health [4]. Mammals
possess seven sirtuins, encoded by SIRT1–SIRT7. As the excit-
ing targets for CVD management, Sirtuins are expressed
broadly in the nucleus and cytoplasm of multiple tissues and
highly expressed in the heart tissue and the vascular endothe-
lium [5]. SIRT1 is the best-known member of the sirtuin family
which belongs to the sirtuin family of nicotinamide adenine
dinucleotide (NAD+)-dependent protein deacetylases, whose
activation appears beneﬁcial for aging associated metabolic,
inﬂammatory, and cardiac diseases, and to increase lifespan
in model organisms [6].
SIRT1 has protective effects against CVD and through its
deacetylase activity plays pivotal roles in regulating numerous
biological functions including regulation of energy, detoxiﬁca-
tion of oxidative stress, promotion of angiogenesis, intracellu-
lar Ca2+ handling, promoting cell survival and longevity and
induction of autophagy [7]. SIRT1 exerts its function through
deacetylation of important substrates such as p53, Forkhead
box class O (FOXO) transcription factors, peroxisome prolif-
erator activated receptor (PPAR)g co-activator 1a (PGC-1a),
nuclear factor (NF)-jB and others, which are all closely linked
to the age-related diseases including CVD [6]. Cardiac-speciﬁc
upregulation of SIRT1 has extensively been shown to prevent
atherogenesis, premature cardiac hypertrophy, apoptosis, cardiac
ﬁbrosis, cardiac dysfunction, and expression of cellular senes-
cence markers, which increases with age [8–10]. However, SIRT1
inhibition has been associated with developmental abnormalities,
including septal and valvular heart defects, vascular dysfunction,
arterial thrombosis and alterations in ﬁbrinolysis [11].
SIRT1 is mapped on chromosome 10 (10q21.3) and poly-
morphic variants of this gene have been studied in the suscep-
tibility of several disorders, such as CVD [12], Type 2 diabetes
(T2D) [13,14], glucose tolerance [15], overweight [16], lipid
proﬁles and coronary artery [17], body fat and blood pressure
[18], carotid plaque [19] and aging [20]. Promoter region vari-
ants may account for differential SIRT1 expression, rendering
individuals susceptible to certain pathologies. Two SIRT1
rs3758391 T/C and rs369274325 G/T polymorphisms have
been identiﬁed near the 50 end of the SIRT1 gene. Up until
now, the rs3758391 T allele has been associated with T2D
[14] as well as aging [20], however, no study has yet evaluated
the impact of these two polymorphisms on the risk of CVD.
Therefore, due to the involvement of SIRT1 in physiological
processes underlying protection against CVD, the aim of this
study was to analyze the SIRT1 promoter region polymor-
phisms rs3758391 T/C and rs369274325 G/T in relation to
genetic susceptibility to CVD.
2. Subjects and methods
2.1. Patients and clinical data collection
In the present case–control study, a total of 250 CVD patients
and 250 healthy subjects were recruited for the genotyping ofSIRT1 gene polymorphisms. The CVD patients were recog-
nized as the presence of identiﬁed myocardial infarction, coro-
nary insufﬁciency (unstable angina with demonstrated
ischemic electrocardiographic changes), death due to CHD,
or atherothrombotic stroke. Blood samples were taken after
12 h overnight before cardiovascular procedures. Once regis-
tered, the participants ﬁlled questionnaire forms including
race/ethnic status, demographics and history of cigarette
smoking, hypertension and diabetes mellitus (DM) (Table 1).
Hypertension was determined as systolic blood pressure
>140 mmHg, diastolic blood pressure >90 mmHg or therapy
for hypertension. DM was diagnosed as a fasting blood glu-
cose level >7 mmol/L or current use of hypoglycemic agents
[19]. The study was approved by the institutional review board
of cardiovascular institute, and the participating hospitals. The
local Ethics Committee of the Zahedan University of Medical
Sciences endorsed the project, and written informed permis-
sion was taken from all participants. The work is carried out
in accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involv-
ing humans.2.2. DNA preparation and PCR-based allele genotyping
Blood samples were collected in EDTA-containing tubes and
genomic DNA was isolated from peripheral blood cells by
the salting-out method. TheSIRT1 rs369274325 G/T and
rs3758391 T/C polymorphisms were genotyped by Tetra
ampliﬁcation refractory mutation system-polymerase chain
reaction (T-ARMS-PCR) as well as restriction fragment
length polymorphism (RFLP) methods, respectively. The
T-ARMS-PCR method employs two external primers, for-
ward outer (FO) and reverse outer (RO) producing a control
band and two allele-speciﬁc internal primers (RI and FI).
This method simultaneously ampliﬁes both alleles in one sin-
gle-PCR tube. All primer sequences and fragments size are
listed in Table 2.
PCR was performed by commercially available Prime Taq
premix (Genetbio, South Korea) based on the manufacturer
recommended protocol. Into a 0.2-mL PCR tube with a ﬁnal
volume of 20 lL, 1 ng of template DNA, 1 lL of each primer
(10 lM), 10 lL Taq premix and 6 lL DNase-free water were
added. The Cycling conditions for the SIRT1 rs369274325
G/T were a primary denaturation at 94 C for 5 min followed
by 30 cycles of 45 s at 94 C, annealing temperature for 45 s at
59 C and 45 s at 72 C, with a ﬁnal extension of 5 min at
72 C. The PCR conditions for rs3758391 T/C polymorphism
were 5 min at 94 C followed by 30 cycles of 94 C for 45 s,
56 C for 45 s, 72 C for 45 s followed by a ﬁnal extension step
for 5 min at 72 C. PCR products were segregated using stan-
dard electrophoresis on a 2% agarose gel containing 0.5 lg/
mL ethidium bromide and images were taken under UV light.
The products size for SIRT1 rs369274325 G/T was 229 bp for
the G allele and 152 bp for the T allele, whereas the product
size for the two outer primers (control band) was 336 bp
(Fig. 1). The amplicon size for the rs3758391 T/C was
241 bp, and the PCR product was digested with restriction
enzyme Hin1II. After the RFLP enzyme digestion, two
146 bp and 95 bp (T allele) products were produced from the
241 bp amplicon (C allele) (Fig. 2).
Table 1 Clinical and biochemical data in CVD case and control subjects.
CVD patients Controls P-Value
No 250 250
Age (years) 59.7 ± 11.2 64.2 ± 10.1 <0.001
Men, n (%) 147 (58.8) 97 (38.8) <0.001
Ethnicity 0.002
Fars 159 (63.6) 159 (63.6)
Balouch 63 (25.2) 82 (32.8)
Others 28 (11.2) 9 (3.6)
Current smoking, n (%) 79 (31.6) 61 (24.4) 0.045
History of hypertension, n (%) 106 (42.4) 61 (24.4) <0.001
History of diabetes mellitus, n (%) 106 (42.4) 37 (14.8) <0.001
Table 2 Primers sequence for genotyping of SIRT1 rs3758391 C/T and rs369274325 G/T gene polymorphisms (Using the FastPCR
Software).
SNPs Primer sequence (50 to 30) Amplicons size
SIRT1 rs3758391 T/C
SIRT1-F GTCACGCAGGTAATTGATGCAG 241 bp
SIRT1-R GGCTTAGTGGAAAGCCCTTC
SIRT1 rs369274325 G/T
SIRT1-FO TAGGTTCCATACCCCATGAAG 336 bp
SIRT1-RO CATTACTCTTAGCTGCTTGGTC
SIRT1-FI (G allele) GAATTGTGTCATAGGTTAGGAGG 229 bp
SIRT1-RI (T allele) ACAGCAAAGTTTGGCATATTGAA 152 bp
Figure 2 Electrophoresis photograph of the PCR product of
SIRT1 rs3758391 G/C polymorphism using PCR–RFLP, sample
1: TT; samples 2, 3: CT; samples 4, 5: CC. The ladder was 100-bp
from Amplicon Co.
Figure 1 Electrophoresis photograph of PCR products of
SIRT1 rs369274325 G/T polymorphism using Tetra-ARMS-
PCR, all samples GG. The ladder was 100-bp from Amplicon Co.
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Statistical analyses were executed using the SPSS program for
Windows version 18.0 (SPSS, Chicago, IL, USA). Statistical
analyses of continuous variables of demographic data were
evaluated by Student’s t-test. Genotypes and allele frequencies
were computed using the X2 or Fisher probability test statistic.
ORs and 95% CIs were calculated with the use of binary logis-
tic regression analyses. Adjusted ORs were stratiﬁed by age,
sex, ethnicity, history of CVD, hypertension, DM and current
smoking. A two-sided P-value less than 0.05 was considered
statistically signiﬁcant.3. Results
The present study demonstrated that the demographics char-
acteristics of CVD patients and healthy controls were statisti-
cally different which included age, sex, ethnicity, history of
CVD, hypertension, DM and smoking status (Table 1). The
frequency distribution of the SIRT1 rs3758391 T/C and
rs369274325 G/T genotypes and alleles was compared between
250 CVD cases and 250 controls.
Table 3 The genotype and allele frequencies of SIRT1 rs3758391 C/T and rs369274325 G/T variations between CVD patients and
controls.
Polymorphism CVD patients n (%) Controls n (%) *Odds ratio (95% CI) *P-Value
SIRT1 rs3758391 T/C
Additive
TT 71 (28) 68 (27) 1.00 –
CT 131 (53) 167 (67) 0.75 (0.50–1.12) 0.181
CC 48 (19) 15 (6.0) 3.06 (1.57–5.98) 0.001#
Dominant
TT 71 (28) 68 (27) 1.00 –
CT + CC 179 (72) 182 (73) 0.94 (0.64–1.39) 0.842
Recessive
TT + CT 202 (81) 235 (94) 1.00 –
CC 48 (19) 15 (6.0) 3.72 (2.02–6.85) 0.001#
Alleles
T 273 (54.6) 303 (60.6) 1.00 –
C 227 (45.4) 197 (39.4) 1.28 (0.99–1.64) 0.063
SIRT1 rs369274325 G/C
GG 250 (100) 250 (100) 1.00 –
GT 0 0 – –
TT 0 0 – –
Alleles
G 500 (100) 500 (100) 1.00 –
T 0 0 – –
* Adjusted ORs were stratiﬁed by age, sex, race, and history of hypertension, DM and smoking.
# P-Values below 0.05 were considered statistically signiﬁcant.
Table 4 Demographic characteristics of CVD patients according to SIRT1 rs3758391 C/T genotypes.
SIRT1 rs3758391 C/T P-Value
TT CT + CC
Age (years) 58.3 60.3 0.195
Sex 0.054
Male, n (%) 35 (24) 112 (76)
Female, n (%) 36 (35) 67 (65)
Ethnicity 0.880
Balouch, % 30.0 70.0
Fars, % 28.3 71.7
Others, % 25.0 75.0
Current smoking, n (%) 27 (38.0) 52 (29.1) 0.111
History of hypertension, n (%) 31 (43.7) 75 (41.9) 0.454
History of Diabetes, n (%) 32 (45.1) 74 (41.3) 0.345
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between two groups regarding genotyping distribution of the
SIRT1 at position rs3758391 T/C in either of additive and
recessive models. In the additive model, the frequency of
rs3758391 CC vs. TT genotype was increased in CVD patients
than in the controls (19% vs. 6%), showing a statistically signif-
icant difference (OR = 3.06, 95% CI: 1.57–5.98, P= 0.001).
Likewise, the recessive model indicated that the carriers of
the CC genotype conferred a higher risk of CVD compared
with those carrying the TT + CT genotype (OR= 3.72, 95%
CI: 2.02–6.85, P= 0.001). At the allelic level, although the C
allele was more prevalent in the patients group than in the con-
trols (45% vs. 39%), the difference did not reach the borderline
of statistical signiﬁcance (OR= 1.28, 95% CI: 0.99–1.64,
P= 0.063) Table 3.
On the other hand, the allelic and genotypic distributions of
the SIRT1 polymorphism at position rs369274325 G/T werenot signiﬁcantly different between CVD patients and controls
with the minor allele frequency (MAF) of 0 in both cases and
controls (P= 1.00).
Table 4 shows the analysis of demographic data of patients
in relation to SIRT1 rs3758391 genotypes. The analysis
revealed that the SIRT1 CT+ CC genotype was more fre-
quent in male subjects than in women, although the difference
was not statistically signiﬁcant (P= 0.054).
Additionally, no association among other risk factors of
CVD and distribution of SIRT1 rs3758391 genotypes was
found (P> 0.05).
4. Discussion
Sirtuins are a unique class of proteins that link the acetylation
status of proteins to a wide variety of diseases including CVD.
SIRT1 exerts its cardioprotective activities through mediating
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pressure, reducing atherosclerosis, heart protection against
oxidative stress and inducing cardiac cell survival and growth,
hence increasing maximum lifespan [21].
SIRT1 plays an essential role in controlling blood pressure
through regulating endothelial nitric oxide (NO) and endothe-
lium dependent vascular tone by deacetylating endothelial
nitric oxide synthase (eNOS). SIRT1 and eNOS co-localize
and co-precipitate in endothelial cells (ECs), and SIRT1
deacetylates eNOS, inducing eNOS activity and mounting
endothelial NO [8]. On the contrary, suppression of SIRT1
in the endothelium of arteries has been shown to reduce endo-
thelium dependent vasodilation and bioavailable NO [22].
However, resveratrol (RSV), a SIRT1 activator, activates
eNOS, improves endothelial function, restores vascular eNOS
activity; hence prevents elevation of blood pressure in animal
models of endothelial dysfunction [6,23]. Trans-resveratrol
(trans-3,4,5-trihydroxystilbene, RSV) is a polyphenol com-
pound which mimics the cardio beneﬁcial functions of SIRT1.
RSV has advantageous effects against ischemia/hypoxia of
cardiomyocytes and protects the heart from ischemic-reperfu-
sion injury through the involvement of SIRT1 [24].
The other critical role of SIRT1 is reducing atherosclero-
sis by mediating several pathways. EC upregulation of
SIRT1 increases eNOS-derived NO and has anti-inﬂamma-
tory functions in ECs and macrophages, downregulating
the expression of several proinﬂammatory cytokines by inter-
fering with the NF-jB signaling pathway. Indeed, SIRT1
deacetylates RelA/p65-NF-jB proteins in macrophages and
also inhibits expression of lectin-like oxidized low-density
lipoprotein (oxLDL) receptor (Lox-1), a scavenger receptor
for oxLDL, preventing macrophage foam cell formation,
hence retarding atherosclerosis [8]. Furthermore, SIRT1 acti-
vates transcription of the liver X receptors (LXR) target gene
encoding the ATP-binding cassette transporter A1 (ACTA1),
which mediates HDL synthesis, reverses cholesterol transport
and decreases the risk of atherosclerosis and cardiovascular
events [6].
In this study we found a signiﬁcant association of CVD
patients with rs3758391 T/C polymorphism in SIRT1 gene.
We found that the CC genotype of SIRT1 rs3758391 polymor-
phism was a risk factor for CVD in both additive and recessive
models, suggesting that the carriers of the CC genotype were at
3- or 3.7-fold increased risk of CVD than subjects with the TT
genotype, respectively. In accordance with our ﬁndings, the
SIRT1 rs3758391 has been associated with the risk of a variety
of diseases including T2D [14], systemic lupus erythematosus
(SLE) morbidity [25] and aging [20]. Cruz et al. [14], observed
a signiﬁcant association of SIRT1 rs3758391 and T2D, sug-
gesting this polymorphism as a risk factor for T2D in a Mex-
ican population. Likewise, Zhang et al. [20] found the
rs3758391/CC to be more common than rs3758391/CT and
rs3758391/TT in the aging subjects with the OR of 3.042,
which supports our ﬁndings in CVD.
The SIRT1 rs3758391 T/C polymorphism is located in the
promoter region, within a putative p53 binding site. The
rs3758391 C allele has been shown to result in a lower binding
afﬁnity for p53 compared to the T allele suggesting that this
variant may be functional. In this context, TT and CT geno-
types were shown to be associated with an increased SIRT1
expression in skeletal muscle of overweight individuals com-
pared to the CC genotype [26]. In our study, the CC genotype(low SIRT1 producer) was more frequent in CVD patients
than in controls, and considering the cardioprotective effects
of SIRT1, this increased frequency may underlie the predispo-
sition of patients to CVD.
Cardiac-speciﬁc expression of SIRT1 has also shown protec-
tion against oxidative stress in the heart tissue through hamper-
ing the myocytes cell death induced by Poly (ADP-ribose)
polymerase-1 (PARP) activation. Intense activation of PARP
by oxidative stress has been associated with a reduced SIRT1
deacetylase activity, and underlies the myocyte cell death con-
tributing to heart failure. In contrast, SIRT1 activators such
as RSV, induced Mn-SOD, and reduced oxidative stress partic-
ipating in cardiomyocyte protection [8,27]. Thus, SIRT1 activa-
tors such as RSV could be considered as novel therapeutic tools
for the treatment of chronic heart failure.
Another important cardioprotective role of SIRT1 is induc-
ing cardiac cell survival and growth. Through decreasing DNA
damage, apoptosis, and cell senescence, SIRT1 plays a critical
role in cardiac development and myocardial cells growth to
maintain cardiac function [8]. Conversely, Sirt1 knockout mice
exhibited developmental abnormalities, including septal and
valvular heart defects, emphasizing the SIRT1 role in patho-
logical hearts [11].
Up till now, only a few human genetic studies of SIRT1
polymorphisms in CVD have been published, and our ﬁnding
is the ﬁrst report suggesting the association of SIRT1
rs3758391 T/C polymorphism with susceptibility to CVD. In
conclusion, our study suggests that the SIRT1 rs3758391 CC
genotype may confer an increased risk for the CVD in both
additive and recessive models in this Iranian population. Addi-
tional researches on larger populations are warranted to vali-
date our results.Acknowledgements
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